Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...
The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback